Scarica l'app Stockscreener
0.6271
4.96%
-0.0327
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.6598
Aprire:
$0.7
Volume 24 ore:
1.36M
Relative Volume:
0.68
Capitalizzazione di mercato:
$6.67M
Reddito:
-
Utile/perdita netta:
$-9.64M
Rapporto P/E:
-0.0906
EPS:
-6.9236
Flusso di cassa netto:
$-10.11M
1 W Prestazione:
-3.43%
1M Prestazione:
-31.88%
6M Prestazione:
-77.92%
1 anno Prestazione:
-77.20%
Intervallo 1D:
$0.6271
$0.71
Intervallo di 1 settimana:
$0.62
$0.7124
Portata 52W:
$0.54
$4.10
Gt Biopharma Inc Stock (GTBP) Company Profile
Nome
Gt Biopharma Inc
Settore
Industria
Telefono
(800) 304-9888
Indirizzo
505 MONTGOMERY STREET, SAN FRANCISCO
Confronta GTBP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| 0.2846 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.49 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.17 | 303.77M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
5.04 | 221.34M | 0 | 0 | 0 | 0.00 |
|
DAVEW
Dave Inc
|
0.67 | 0 | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
46.76 | 0 | 0 | 0 | 0 | 0.00 |
Gt Biopharma Inc Stock (GTBP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-02 | Iniziato | ROTH MKM | Buy |
| 2021-05-24 | Iniziato | H.C. Wainwright | Buy |
| 2021-04-13 | Iniziato | B. Riley Securities | Buy |
| 2021-03-17 | Iniziato | ROTH Capital | Buy |
Gt Biopharma Inc Borsa (GTBP) Ultime notizie
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis - GlobeNewswire Inc.
GT Biopharma Inc Stock Analysis and ForecastEarnings Surprise Analysis & Free Get High Impact Recommendations - earlytimes.in
GT Biopharma Inc OXIA Stock Analysis and ForecastStraddle and Strangle Trades & Free High Yield Portfolio Picks - earlytimes.in
Platform Technologies Drive $211B Surge in Precision Cancer Treatment - marketscreener.com
GT Biopharma, Inc. Reports Continued Progress with Its Phase 1 Clinical Trial of GTB-3650 - marketscreener.com
THE REALITY CHECK: 5 Assets Delivering Proof in a Speculative Market - The Manila Times
What is GT Biopharma Inc (GTBP) Stock Return on Shareholders’ Capital? - setenews.com
GT Biopharma (GTBP) Stock Analysis Report | Financials & Insights - Benzinga
Why GT Biopharma Inc. (OXIA) stock could rally stronglyJuly 2025 Recap & Daily Price Action Insights - Newser
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points - KamloopsBCNow
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points (2025-12-04) - Seeking Alpha
What technical charts say about GT Biopharma Inc. stockTrade Volume Summary & Free Technical Pattern Based Buy Signals - Newser
What is the fair value estimate for GT Biopharma Inc. (OXIA) stock in 2025July 2025 Trade Ideas & Daily Risk Controlled Trade Plans - Newser
The growth track for GT Biopharma Inc (GTBP) has changed recently - Setenews
What Wall Street predicts for GT Biopharma Inc. stock priceTrade Entry Report & Fast Exit and Entry Strategy Plans - Newser
Is GT Biopharma Inc. (OXIA) stock a buy on weaknessWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - Newser
How supply chain issues affect GT Biopharma Inc. stockRate Hike & Consistent Income Trade Ideas - Newser
How reliable is GT Biopharma Inc. (OXIA) stock dividend growthWeekly Volume Report & AI Forecast for Swing Trade Picks - Newser
What drives GT Biopharma Inc stock priceShort Interest Overview & Superior Trading Portfolio - earlytimes.in
GT Biopharma faces Nasdaq bid-price deficiency, eyes compliance options - Stock Titan
A History of Outperforming Analyst Forecasts and Beating the Odds: GT Biopharma Inc (GTBP) - Setenews
GT Biopharma shares advance as flagship GTB 3650 trial escalates to next dose level - MSN
GT Biopharma (GTBP) Price Target Decreased by 27.27% to 8.16 - MSN
How GT Biopharma Inc. (OXIA) stock responds to job market shiftsMarket Growth Report & Growth Oriented Trade Recommendations - newser.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Is GT Biopharma Inc. (OXIA) stock a fit for income portfoliosPortfolio Risk Summary & Risk Adjusted Swing Trade Ideas - newser.com
Will GT Biopharma Inc. (OXIA) stock extend growth storyWeekly Stock Recap & Daily Profit Maximizing Tips - newser.com
Will GT Biopharma Inc. (OXIA) stock deliver compounding returns2025 Earnings Surprises & Safe Entry Momentum Tips - newser.com
Is GT Biopharma Inc. stock attractive for income investorsWatch List & Stepwise Entry and Exit Trade Signals - newser.com
Developing predictive dashboards with GT Biopharma Inc. dataChart Signals & Daily Entry Point Alerts - newser.com
Is GT Biopharma Inc. trending in predictive chart models2025 Price Targets & Weekly Stock Breakout Alerts - newser.com
Will GT Biopharma Inc. bounce back from current supportQuarterly Trade Review & Accurate Trade Setup Notifications - newser.com
Is GT Biopharma Inc. (OXIA) stock positioned for secular growth2025 Big Picture & Capital Efficiency Focused Ideas - newser.com
Tools to monitor GT Biopharma Inc. recovery probabilityMarket Risk Report & Real-Time Market Trend Scan - newser.com
GT Biopharma stock rises as Phase 1 trial advances to higher dose - Investing.com Nigeria
Gt Biopharma Inc Azioni (GTBP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):